Healthcare entity
market-trends is the sole category represented across all 2 tracked stories. Of the tracked stories, 1 of 2 also mention ATG-201, the most common co-covered peer. Across a 21-day span, the pace is roughly 0.7 stories per week. Source depth averages 2 original sources per story, versus 3.1 across the same-window beat baseline.
Last mentioned: Mar 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 2 tracked stories. Of the tracked stories, 1 of 2 also mention ATG-201, the most common co-covered peer. Across a 21-day span, the pace is roughly 0.7 stories per week. Source depth averages 2 original sources per story, versus 3.1 across the same-window beat baseline. The 6.5 average consequence score is above the beat benchmark of 5.9 in the same window. We currently track 2 Healthcare stories that mention UCB, published between March 4, 2026 and March 24, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 470 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering UCB. Shared-story counts are live from our verified record — not editorial picks.
Clinical Filings Target
Antengene plans to submit CTAs for ATG-201 in China and Australia by the end of Q1 2026.
Investor Briefings
Antengene hosts conference calls in Chinese and English to discuss the UCB partnership.
Global License Agreement
Antengene and UCB announce exclusive worldwide licensing deal for ATG-201.
Belgian biopharma giant UCB has announced a massive $2 billion investment to establish a new manufacturing plant in suburban Atlanta, creating 330 high-skilled jobs. The move strengthens UCB's U.S. footprint as it scales production for its high-growth immunology portfolio.
UCB has secured exclusive global rights to Antengene's ATG-201, a CD19/CD3 bispecific T-cell engager targeting autoimmune diseases. The agreement includes $80 million in upfront payments and potential milestones exceeding $1.1 billion, validating Antengene's AnTenGager platform.
Source: admin (in) · admin (in)
UCB is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
